What Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Sell
42
NEOG Quote, Financials, Valuation and Earnings
Last price:
$6.50
Seasonality move
:
7.02%
Day range:
$6.19 - $6.61
52-week range:
$3.87 - $18.58
Dividend yield:
0%
P/E ratio:
2,124.15x
P/S ratio:
1.56x
P/B ratio:
0.53x
Volume:
7.3M
Avg. volume:
8.6M
1-year change:
-47.28%
Market cap:
$1.4B
Revenue:
$924.2M
EPS (TTM):
-$2.24
Analysts' Opinion
-
Consensus RatingNeogen has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.00, Neogen has an estimated upside of 38.46% from its current price of $6.50.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $6.50.
Fair Value
-
According to the consensus of 3 analysts, Neogen has 38.46% upside to fair value with a price target of $9.00 per share.
NEOG vs. S&P 500
-
Over the past 5 trading days, Neogen has overperformed the S&P 500 by 11.05% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Neogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neogen revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Neogen reported revenues of $221M.
Earnings Growth
-
Neogen earnings have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter Neogen reported earnings per share of -$0.05.
Enterprise value:
2.2B
EV / Invested capital:
0.61x
Price / LTM sales:
1.56x
EV / EBIT:
82.12x
EV / Revenue:
2.40x
PEG ratio (5yr expected):
-160.49x
EV / Free cash flow:
-49.11x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
20.98x
Gross Profit (TTM):
$442M
Return On Assets:
-11.17%
Net Income Margin (TTM):
-53.56%
Return On Equity:
-16.44%
Return On Invested Capital:
-12.64%
Operating Margin:
2.45%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Income Statement | ||||||
| Revenue | $720.7M | -- | $906M | -- | $221M | |
| Gross Profit | $347.8M | -- | $442M | -- | $110.3M | |
| Operating Income | $32.1M | -- | $24.6M | -- | $5.4M | |
| EBITDA | $93.5M | -- | -$312.6M | -- | $37.4M | |
| Diluted EPS | $0.04 | -- | -$2.24 | -- | -$0.05 | |
| Period Ending | 2021-02-28 | 2022-02-28 | 2023-02-28 | 2024-02-28 | 2025-02-28 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $555.3M | $609.6M | $555.4M | -- | $551.7M | |
| Total Assets | $880.2M | $981.2M | $4.5B | -- | $4B | |
| Current Liabilities | $45.9M | $65.7M | $107.2M | -- | $141.2M | |
| Total Liabilities | $72.5M | $105.7M | $1.4B | -- | $1.4B | |
| Total Equity | $807.7M | $875.5M | $3.1B | -- | $2.7B | |
| Total Debt | -- | -- | $884.7M | -- | $890.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-02-28 | 2024-02-28 | 2025-02-28 | 2024-02-28 | 2025-02-28 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$29.5M | -- | $68.4M | -- | $19.4M | |
| Cash From Investing | $177.1M | -- | -$100.8M | -- | -$32.4M | |
| Cash From Financing | -$119.4M | -- | $434K | -- | $945K | |
| Free Cash Flow | -$82.3M | -- | -$44.3M | -- | -$13.5M | |
NEOG
Sector
Market Cap
$1.4B
$34.7M
Price % of 52-Week High
34.98%
44.12%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.67%
1-Year Price Total Return
-47.28%
-40.33%
Beta (5-Year)
1.832
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$5.80
200-day SMA
Sell
Level
$12.44
Bollinger Bands (100)
Sell
Level
6.78 - 11.94
Chaikin Money Flow
Buy
Level
23.2M
20-day SMA
Buy
Level
$5.28
Relative Strength Index (RSI14)
Buy
Level
56.20
ADX Line
Buy
Level
34
Williams %R
Sell
Level
-6.0124
50-day SMA
Sell
Level
$7.28
MACD (12, 26)
Sell
Level
-0.30
25-day Aroon Oscillator
Sell
Level
-8
On Balance Volume
Sell
Level
-241.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7485)
Buy
CA Score
(Annual)
Level (0.5434)
Buy
Beneish M-Score
(Annual)
Level (-2.4299)
Buy
Momentum Score
Level (2)
Buy
Ohlson Score
Level (-0.6069)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, Neogen performs diagnostics to detect unintended substances in food and animal feed, such as pathogens, allergens, and drug residues, for food and feed processing companies. In animal safety, Neogen sells veterinary instruments, pharmaceuticals, disinfectants, and genomics tests for animals, including cattle, horses, and canines. Sales in the United States account for maximum revenue, and it also has its presence in United Kingdom and other countries.
Stock Forecast FAQ
In the current month, NEOG has received 2 Buy ratings 1 Hold ratings, and 0 Sell ratings. The NEOG average analyst price target in the past 3 months is $9.00.
-
Where Will Neogen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neogen share price will rise to $9.00 per share over the next 12 months.
-
What Do Analysts Say About Neogen?
Analysts are divided on their view about Neogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neogen is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Neogen's Price Target?
The price target for Neogen over the next 1-year time period is forecast to be $9.00 according to 3 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is NEOG A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neogen is a Buy. 2 of 3 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NEOG?
You can purchase shares of Neogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neogen shares.
-
What Is The Neogen Share Price Today?
Neogen was last trading at $6.50 per share. This represents the most recent stock quote for Neogen. Yesterday, Neogen closed at $6.50 per share.
-
How To Buy Neogen Stock Online?
In order to purchase Neogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Which Stocks Are Recession-Proof?
Fears of a recession prevailed in Q2 2025 when the…
Is Gartner a Safe Stock to Own?
Gartner (NYSE:IT) is among the world’s largest consulting, research and…
Stock Ideas
Buy
72
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 38x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Buy
70
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 42x
Alerts
Buy
64
RGC alert for May 13
Regencell Bioscience Holdings [RGC] is down 31.81% over the past day.
Buy
82
NRG alert for May 13
NRG Energy [NRG] is up 4.09% over the past day.
Sell
44
GDXU alert for May 13
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 0.05% over the past day.
